AU Patent

AU2003226356A1 — Prevention of brain inflammation as a result of induced autoimmune response

Assigned to Ramot at Tel Aviv University Ltd · Expires 2003-10-27 · 23y expired

What this patent protects

Patent listed against atrasentan-hydrochloride.

Drugs covered by this patent

atrasentan-hydrochloride (ATRASENTAN HYDROCHLORIDE)

Patent Metadata

Patent number: AU2003226356A1
Jurisdiction: AU
Classification: —
Expires: 2003-10-27
Drug substance claim: No
Drug product claim: No
Assignee: Ramot at Tel Aviv University Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.